Advances in Inflammatory Bowel Diseases - AIBD

Attendees, exhibitors & solutions

Who this event is for

Industry trends

Key trends shaping this market and its wider industry.

Arrival airports

Choose from the following airports, with convenient access to the event and venue.

Hotel tiers

A range of accommodation options near the venue and across key areas.

Local transport

Get around the city with these convenient transport options.

Frequently asked

Glossary

1

AIBD

Advances in Inflammatory Bowel Diseases, the annual Orlando meeting focused on clinical management of Crohn's disease and ulcerative colitis. The acronym is used both for the conference and for its published programme.

2

IBD (inflammatory bowel disease)

The umbrella term for chronic immune-mediated inflammation of the gastrointestinal tract, chiefly Crohn's disease and ulcerative colitis. Most AIBD sessions address diagnosis, treatment sequencing or long-term monitoring of these two conditions.

3

Crohn's disease

A transmural, segmental form of IBD that can affect any part of the digestive tract from mouth to anus, often with stricturing or fistulising behaviour. Programmes at AIBD typically cover ileal and colonic disease phenotypes separately because treatment strategy differs.

4

Ulcerative colitis

Continuous mucosal inflammation limited to the colon, starting at the rectum and extending proximally to a variable degree. Extent (proctitis, left-sided, extensive) drives both drug choice and surveillance intervals discussed in the sessions.

5

Mucosal healing

Endoscopic resolution of visible inflammation, now a core treatment goal rather than an optional bonus. AIBD content repeatedly frames mucosal healing as the endpoint that correlates with fewer surgeries and fewer flares.

6

Treat-to-target

A management strategy in which predefined endpoints (clinical response, biomarker normalisation, endoscopic remission) are checked at fixed intervals and therapy is adjusted when a target is missed. The approach underpins most AIBD therapeutic decision sessions.

7

Clinical remission

Absence of active symptoms such as diarrhoea, rectal bleeding and abdominal pain, measured with indices like the CDAI or partial Mayo score. Sessions pair symptom scores with objective markers because symptoms alone can understate or overstate inflammation.

8

Endoscopic remission

Objective healing seen at colonoscopy or sigmoidoscopy, scored with instruments such as the SES-CD or endoscopic Mayo subscore. Considered a deeper and more durable target than symptom control.

9

Biologic therapy

Protein-based drugs directed at a specific inflammatory pathway, including anti-TNF agents, anti-integrin antibodies and interleukin inhibitors. AIBD content addresses positioning, immunogenicity and loss of response across these classes.

10

Biosimilar

A follow-on biologic approved after patent expiry and used interchangeably with the originator in many markets. Practical questions of switching, tracking and payer rules are recurring topics for prescribers and infusion staff.

11

IL-23 inhibitor

A drug class blocking the p19 subunit of interleukin-23, used in moderate-to-severe Crohn's disease and ulcerative colitis. Sequencing against anti-TNF and integrin therapy is a standard discussion point in the advanced-therapy sessions.

12

JAK inhibitor

Small-molecule drugs blocking Janus kinase signalling, used in ulcerative colitis and Crohn's disease with labelling that requires attention to thrombosis, infection and malignancy risk. Safety monitoring features heavily in case-based teaching.

13

S1P receptor modulator

An oral class that sequesters lymphocytes in lymph nodes, available for ulcerative colitis and associated with cardiac, ophthalmic and hepatic monitoring requirements. Often compared with JAK inhibitors when patients prefer oral therapy.

14

Therapeutic drug monitoring

Measuring drug trough levels and anti-drug antibodies to explain loss of response and guide dose intensification or class switching. Frequently covered in AIBD pharmacology and case-discussion formats.

15

Pouchitis

Inflammation of an ileal pouch created after colectomy, common in patients with ulcerative colitis and a distinct management problem from the original disease. Dedicated surgical and gastroenterology sessions address pouch surveillance.

16

Dysplasia surveillance

Structured colonoscopic screening, often with chromoendoscopy and targeted biopsies, for patients with long-standing colonic IBD who carry elevated colorectal cancer risk. Surveillance intervals and technique are recurring AIBD topics.

17

Extra-intestinal manifestations

IBD-related conditions outside the gut, including arthropathy, erythema nodosum, pyoderma gangrenosum, uveitis and primary sclerosing cholangitis. Multidisciplinary sessions at AIBD pair gastroenterology with dermatology, rheumatology and hepatology views.

18

Advanced practice provider (APP)

Nurse practitioners and physician assistants who manage much of the day-to-day IBD caseload in clinics and infusion centres. APP-targeted content on therapy initiation, monitoring and patient counselling is a regular feature of IBD congresses.